Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Phase 1b: Multiple Ascending Dose Study (NCT03014609) Study Title: "Safety, Tolerability, PK and PD of Multiple Doses of Cagrilintide in Subjects With Type 2 Diabetes" Status: Completed Phase: Phase 1b Enrollment: 56 participants with T2D Study Period: 2017-2018 Design: Randomized, double-blind, placebo-controlled Duration: 12 weeks Dose Range: 0.3-4.5 mg SC weekly Population: T2D, BMI 25-40, HbA1c 7-10% Key Results: Weight Loss: 6.0 kg (4.5 mg dose) vs
The scale of its clinical program, the magnitude of its effects, and its proven cardiovascular benefit represent a genuine step-change in what pharmacotherapy for obesity can achieve
Additional tests may include full blood count (to check for macrocytic anaemia), methylmalonic acid and homocysteine levels (which rise in B12 deficiency), and tests for intrinsic factor antibodies if pernicious anaemia is suspected
In one mouse study, researchers found that the peptide reduced the pain felt by the animals in their paws when placed on a mildly hot plate. The authors explained that this could be because GHK is similar in structure to cimetidine, a histamine H2 receptor antagonist sometimes given to reduce pain in certain digestive conditions.3 10 In rodents, doses as low as 0.5mg/kg were found to be effective in delivering these anti-pain effects.25 In a 70kg human, an equivalent dose would be around 5.6mg, though thats likely higher than necessary: pharmaceutical-grade GHK-Cu normally ranges from 0.5 mg to 2.5mg per injection
